Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosisHanneke C. Kluin‐Nelemans, Wolfgang R. Sperr, Mohamad Jawhar et al.|Theranostics|2020Cited by 43
Prognostic value of baseline and early response FDG-PET/CT in patients with refractory and relapsed aggressive B-cell lymphoma undergoing CAR-T cell therapyThomas Georgi, Vladan Vučinić, Lars Kurch et al.|Journal of Cancer Research and Clinical Oncology|2023Cited by 25
Prognostic impact of expression of CD2, CD25, and/or CD30 in/on mast cells in systemic mastocytosis: a registry study of the European Competence Network on MastocytosisAxel Rüfer, Peter Valent, Henning Nilius et al.|Leukemia|2025Cited by 6
Salvage Therapy With Polatuzumab Vedotin, Bendamustine, and Rituximab Prior to Allogeneic Hematopoietic Transplantation in Patients With Aggressive Lymphomas Relapsing After Therapy With Chimeric Antigen Receptor T-Cells—Report on Two CasesKristin Gerhardt, Vladan Vučinić, Sabine Leiblein et al.|Frontiers in Oncology|2021Cited by 6
The Differences between Ide-Cel and Cilta-Cel in Relapsed Myeloma at Single Cell ResolutionDavid Fandrei, Maximilian Merz, Michael Rade et al.|Blood|2024Cited by 4